Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
about
Salinomycin as a drug for targeting human cancer stem cellsUnexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsThe links between insulin resistance, diabetes, and cancerAdvances in targeting signal transduction pathwaysThe anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse modelHER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Obesity and cancer--mechanisms underlying tumour progression and recurrenceEffects of metformin on retinoblastoma growth in vitro and in vivo.Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells.Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis.Ovarian tumor-initiating cells display a flexible metabolismLuteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentEffects of metformin on CD133+ colorectal cancer cells in diabetic patientsMetformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumorsCytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition.Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancerMetformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogsStudying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment StrategiesEndoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosineSelective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivoMetformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisMetabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cellsAnti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.Metformin induces a senescence-associated gene signature in breast cancer cells.Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metforminLinked-in: design and efficacy of antibody drug conjugates in oncology
P2860
Q21285139-1F7F0B63-74CC-4359-8CF8-70C46B57C881Q26750845-BC5F69A9-4F2E-4603-BDCF-583794FCEA16Q26852910-DBB2F4E9-E8BF-429C-BF31-CC7EE24A0E0EQ27686983-412A3C80-D571-41FA-BE07-09CB8F9969A7Q28539926-1197AAA3-18B0-46FB-9A0E-0338492EA3C7Q33737278-CBEA7F2B-07C5-4FE0-A1EE-8A8305508798Q34103963-DDD05168-0BCF-445D-A23F-8B7C1753BA56Q34425077-F621776B-9E04-44BA-9CE3-45EA3E0B4FF3Q34432841-99CB65A8-44B8-4258-900B-B4AA94E7EEADQ34483548-141F3716-A976-4350-95A6-2462570FA5F5Q34654807-9DFE7892-E4F3-4338-B3CB-8DAE2A89103AQ34658326-F3646480-47AB-43AD-9633-D500A0BB3CDBQ34675192-BC29CA3D-F958-44E0-964D-580E113ED6F1Q34956497-A0FD0E7D-CFAF-4FDA-9004-A7E1698FCA93Q34957274-5F612021-205A-4549-968C-A906D2430543Q35053962-857EB236-A277-4BE6-B705-70FEEE7344D2Q35115554-709A98F1-5EA8-4FD2-9B64-AB76171FFA85Q35287351-8CA18C3D-986E-4F12-8304-03137291D3BDQ35425337-E205BC84-43D5-4EDF-BDEF-CABA9BF8D1FAQ35740160-6DF8E4A4-FAF6-4E72-82B7-8C0FE75A9C42Q35781432-6563DC1D-02E1-4253-83DB-CF730A81E7EFQ35832214-D1B0F04B-104C-456B-9B80-2EF0CDA0001CQ35835794-F5CD3999-27FE-4641-A1D6-89785DD66D8EQ35932396-440CF3D4-EB6C-4FA7-9EE8-91383DECFB27Q35982489-6CBD005A-4417-4073-A498-25B26ACAA1BCQ35987417-5A0A56C8-83D0-4602-9799-79509E9D46F5Q36021000-7B339DC3-6AD7-4C7F-9B7D-7B360ECFE1E2Q36078840-113D0B93-5E78-4EF7-ACDF-04BB0F978B2FQ36209145-62B9630F-376C-41BB-8470-80029BFA318EQ36426509-CA7CEFB6-63FC-4EA1-B467-41BA51E8EDCAQ36544839-D44B27EE-F795-48EB-B9A7-4CEF75F48FA8Q36604614-5FF852D6-BCB2-4367-9BDD-A3A493679A3EQ36618624-D24E9DE6-9647-4FE8-AC4E-7C8A2EC49251Q36678490-B21AED22-D2F4-4384-B9E7-03B3378A99B3Q36781090-06008A55-DA8A-4716-AE56-63EF81B43C82Q36815271-53E2BBB4-A733-4BAF-8090-D936A2A5D3D0Q36922465-12FF85D3-FF89-484E-8994-CE3334C46843Q36926125-C6E05EDD-F9DF-4FF2-9985-9BFADAE92BD8Q37001540-DA42F399-2565-4FB2-B568-DDC59E4F3C79Q37029370-7D24F744-10F3-4D39-BBD8-ECAE7864284C
P2860
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Metformin-induced preferential ...... uman breast cancer xenografts.
@ast
Metformin-induced preferential ...... uman breast cancer xenografts.
@en
type
label
Metformin-induced preferential ...... uman breast cancer xenografts.
@ast
Metformin-induced preferential ...... uman breast cancer xenografts.
@en
prefLabel
Metformin-induced preferential ...... uman breast cancer xenografts.
@ast
Metformin-induced preferential ...... uman breast cancer xenografts.
@en
P2093
P2860
P356
P1433
P1476
Metformin-induced preferential ...... uman breast cancer xenografts.
@en
P2093
Alejandro Vazquez-Martin
Bruna Corominas-Faja
Christina Oliveras-Ferraros
Javier A Menendez
Joan Dorca
Joaquim Bosch-Barrera
Silvia Cufi
P2860
P304
P356
10.18632/ONCOTARGET.488
P407
P577
2012-04-01T00:00:00Z